PARIS (Reuters) – Valneva on Tuesday reported positive results for its COVID-19 vaccine in early stage clinical trials and said it planned to launch a Phase Three trial this month. The French drugmaker, whose shot uses the technology behind its licensed Japanese encephalitis vaccine, tested its vaccine in 153 adults with three dose levels based